| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Screening and prostate-cancer mortality in a randomized European study.
|
N Engl J Med
|
2009
|
35.94
|
|
2
|
Prostate-cancer mortality at 11 years of follow-up.
|
N Engl J Med
|
2012
|
16.91
|
|
3
|
Quality-of-life effects of prostate-specific antigen screening.
|
N Engl J Med
|
2012
|
7.21
|
|
4
|
Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes.
|
BMJ
|
2014
|
4.75
|
|
5
|
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.
|
Eur Urol
|
2012
|
4.48
|
|
6
|
Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).
|
Eur Urol
|
2012
|
4.07
|
|
7
|
A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.
|
J Urol
|
2010
|
3.79
|
|
8
|
Infectious complications and hospital admissions after prostate biopsy in a European randomized trial.
|
Eur Urol
|
2012
|
3.34
|
|
9
|
Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study.
|
Eur Urol
|
2012
|
3.07
|
|
10
|
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly.
|
Eur Urol
|
2008
|
2.92
|
|
11
|
Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.
|
Urology
|
2002
|
2.87
|
|
12
|
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
|
Clin Cancer Res
|
2010
|
2.87
|
|
13
|
Balancing the harms and benefits of early detection of prostate cancer.
|
Cancer
|
2010
|
2.71
|
|
14
|
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
|
Eur Urol
|
2008
|
2.66
|
|
15
|
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.
|
Eur Urol
|
2010
|
2.47
|
|
16
|
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
|
Eur Urol
|
2009
|
2.31
|
|
17
|
Does PSA velocity predict prostate cancer in pre-screened populations?
|
Eur Urol
|
2006
|
2.24
|
|
18
|
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC.
|
Int J Cancer
|
2010
|
2.15
|
|
19
|
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care.
|
Eur Urol
|
2012
|
2.05
|
|
20
|
Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics.
|
Eur Urol
|
2007
|
2.02
|
|
21
|
Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers.
|
Eur Urol
|
2013
|
2.01
|
|
22
|
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
|
Eur Urol
|
2008
|
1.94
|
|
23
|
No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer.
|
BJU Int
|
2010
|
1.94
|
|
24
|
The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
|
Eur Urol
|
2008
|
1.92
|
|
25
|
Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam.
|
Eur Urol
|
2011
|
1.83
|
|
26
|
Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.
|
J Natl Cancer Inst
|
2010
|
1.83
|
|
27
|
Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome.
|
Eur Urol
|
2006
|
1.80
|
|
28
|
Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
|
Eur Urol
|
2013
|
1.73
|
|
29
|
Risk-based prostate cancer screening.
|
Eur Urol
|
2011
|
1.64
|
|
30
|
Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
|
BJU Int
|
2012
|
1.62
|
|
31
|
Do anxiety and distress increase during active surveillance for low risk prostate cancer?
|
J Urol
|
2010
|
1.61
|
|
32
|
Prospective validation of active surveillance in prostate cancer: the PRIAS study.
|
Eur Urol
|
2007
|
1.57
|
|
33
|
Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
|
Eur Urol
|
2008
|
1.56
|
|
34
|
Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.
|
BJU Int
|
2009
|
1.56
|
|
35
|
ERSPC and PLCO prostate cancer screening studies: what are the differences?
|
Eur Urol
|
2010
|
1.55
|
|
36
|
Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
|
Eur Urol
|
2006
|
1.54
|
|
37
|
Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.
|
Urology
|
2006
|
1.51
|
|
38
|
Anxiety and distress during active surveillance for early prostate cancer.
|
Cancer
|
2009
|
1.49
|
|
39
|
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
|
World J Urol
|
2011
|
1.42
|
|
40
|
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
|
Eur J Cancer
|
2009
|
1.41
|
|
41
|
The REDUCE Trial.
|
Eur Urol
|
2010
|
1.39
|
|
42
|
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
|
BJU Int
|
2013
|
1.39
|
|
43
|
ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.
|
Mod Pathol
|
2011
|
1.31
|
|
44
|
The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.
|
BJU Int
|
2008
|
1.28
|
|
45
|
Towards an optimal interval for prostate cancer screening.
|
Eur Urol
|
2011
|
1.27
|
|
46
|
A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
|
Clin Cancer Res
|
2010
|
1.24
|
|
47
|
Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
|
Eur Urol
|
2007
|
1.18
|
|
48
|
Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
|
Eur Urol
|
2011
|
1.16
|
|
49
|
Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?
|
Cancer
|
2010
|
1.13
|
|
50
|
Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study.
|
Invest Radiol
|
2014
|
1.12
|
|
51
|
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.
|
BMC Med
|
2014
|
1.11
|
|
52
|
Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.
|
J Urol
|
2005
|
1.08
|
|
53
|
Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
|
Eur Urol
|
2008
|
1.08
|
|
54
|
4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
|
J Urol
|
2005
|
1.07
|
|
55
|
Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
|
Eur Urol
|
2005
|
1.06
|
|
56
|
Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies.
|
Eur Urol
|
2009
|
1.05
|
|
57
|
Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
|
Curr Opin Urol
|
2009
|
1.04
|
|
58
|
Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations.
|
Cancer
|
2007
|
1.04
|
|
59
|
Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
|
Urology
|
2004
|
1.02
|
|
60
|
Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
|
BJU Int
|
2005
|
1.01
|
|
61
|
Defining the threshold for significant versus insignificant prostate cancer.
|
Nat Rev Urol
|
2013
|
1.00
|
|
62
|
Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer.
|
Eur Urol
|
2009
|
0.99
|
|
63
|
Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
|
BJU Int
|
2011
|
0.98
|
|
64
|
Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
|
Prostate
|
2006
|
0.95
|
|
65
|
Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
|
BJU Int
|
2009
|
0.94
|
|
66
|
Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population.
|
J Urol
|
2006
|
0.94
|
|
67
|
Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
|
World J Urol
|
2012
|
0.94
|
|
68
|
Defining increased future risk for prostate cancer: evidence from a population based screening cohort.
|
J Urol
|
2008
|
0.93
|
|
69
|
Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
|
BJU Int
|
2011
|
0.93
|
|
70
|
Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.
|
J Med Screen
|
2013
|
0.92
|
|
71
|
Screening for prostate cancer: early detection or overdetection?
|
Annu Rev Med
|
2011
|
0.92
|
|
72
|
The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer.
|
BJU Int
|
2008
|
0.90
|
|
73
|
A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels.
|
Psychooncology
|
2014
|
0.89
|
|
74
|
Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality.
|
J Med Screen
|
2012
|
0.89
|
|
75
|
Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease.
|
Prostate
|
2013
|
0.89
|
|
76
|
Active surveillance for low-risk prostate cancer.
|
Crit Rev Oncol Hematol
|
2012
|
0.89
|
|
77
|
Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer.
|
Int J Cancer
|
2006
|
0.89
|
|
78
|
Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam).
|
Int J Cancer
|
2010
|
0.89
|
|
79
|
Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
|
J Urol
|
2010
|
0.87
|
|
80
|
Prediction of prostate cancer in unscreened men: external validation of a risk calculator.
|
Eur J Cancer
|
2010
|
0.87
|
|
81
|
Tumour features in the control and screening arm of a randomized trial of prostate cancer.
|
Eur Urol
|
2005
|
0.87
|
|
82
|
Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
|
BJU Int
|
2012
|
0.86
|
|
83
|
Excess all-cause mortality in the evaluation of a screening trial to account for selective participation.
|
J Med Screen
|
2013
|
0.86
|
|
84
|
Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years?
|
BJU Int
|
2007
|
0.86
|
|
85
|
Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness.
|
J Urol
|
2004
|
0.86
|
|
86
|
Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.
|
Prostate
|
2007
|
0.86
|
|
87
|
Prostate cancer epidemic in sight?
|
Eur Urol
|
2012
|
0.86
|
|
88
|
Rotterdam randomized pilot studies of screening for prostate cancer--an overview after 10 years.
|
J Natl Cancer Inst
|
2005
|
0.85
|
|
89
|
Compliance with biopsy recommendations of a prostate cancer risk calculator.
|
BJU Int
|
2011
|
0.84
|
|
90
|
Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
|
Eur J Cancer
|
2010
|
0.84
|
|
91
|
Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
|
BJU Int
|
2012
|
0.84
|
|
92
|
Disease insight and treatment perception of men on active surveillance for early prostate cancer.
|
BJU Int
|
2009
|
0.83
|
|
93
|
Prostate cancer in the Swedish section of ERSPC--evidence for less metastases at diagnosis but not for mortality reduction.
|
Eur Urol
|
2006
|
0.82
|
|
94
|
Disease-specific mortality may underestimate the total effect of prostate cancer screening.
|
J Med Screen
|
2010
|
0.82
|
|
95
|
Expert Involvement Predicts mHealth App Downloads: Multivariate Regression Analysis of Urology Apps.
|
JMIR Mhealth Uhealth
|
2016
|
0.81
|
|
96
|
Defining and predicting indolent and low risk prostate cancer.
|
Crit Rev Oncol Hematol
|
2011
|
0.81
|
|
97
|
Active surveillance: oncologic outcome.
|
Curr Opin Urol
|
2013
|
0.81
|
|
98
|
Predictive models in diagnosing indolent cancer.
|
Cancer
|
2009
|
0.81
|
|
99
|
Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality.
|
Can J Urol
|
2011
|
0.80
|
|
100
|
Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
|
Prostate
|
2006
|
0.80
|
|
101
|
Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy.
|
Prostate
|
2011
|
0.80
|
|
102
|
Profiling of antibody production against xenograft-released proteins by protein microarrays discovers prostate cancer markers.
|
J Proteome Res
|
2011
|
0.80
|
|
103
|
Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.
|
BJU Int
|
2011
|
0.79
|
|
104
|
Should prostate-specific antigen screening be offered to asymptomatic men?
|
Expert Rev Anticancer Ther
|
2010
|
0.79
|
|
105
|
Reply from authors re: Michael Baum. Screening for prostate cancer: can we learn from the mistakes of the breast screening experience? Eur Urol 2013;64:540-1: screening for prostate cancer: we have learned and are still learning.
|
Eur Urol
|
2013
|
0.79
|
|
106
|
Sexual function with localized prostate cancer: active surveillance vs radical therapy.
|
BJU Int
|
2012
|
0.79
|
|
107
|
Identifying and characterizing "escapes"-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam).
|
Int J Cancer
|
2011
|
0.78
|
|
108
|
PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making.
|
Asian J Androl
|
2011
|
0.78
|
|
109
|
On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
|
Eur J Cancer
|
2010
|
0.78
|
|
110
|
Updating the prostate cancer risk indicator for contemporary biopsy schemes.
|
Can J Urol
|
2011
|
0.78
|
|
111
|
Epilogue: different approaches for prostate cancer screening in the EU?
|
Eur J Cancer
|
2010
|
0.77
|
|
112
|
What's new in screening in 2015?
|
Curr Opin Urol
|
2016
|
0.77
|
|
113
|
Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
|
Eur Urol
|
2011
|
0.77
|
|
114
|
Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood.
|
PLoS One
|
2012
|
0.77
|
|
115
|
Dutasteride and prostate cancer.
|
N Engl J Med
|
2010
|
0.77
|
|
116
|
Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial.
|
Prostate
|
2007
|
0.76
|
|
117
|
Re: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.
|
BJU Int
|
2008
|
0.75
|
|
118
|
Words of wisdom. Re: PSA density improves prediction of prostate cancer.
|
Eur Urol
|
2014
|
0.75
|
|
119
|
Re: Is a screening interval of every 4 years for prostate cancer acceptable?
|
J Natl Cancer Inst
|
2008
|
0.75
|
|
120
|
Selective detection of aggressive prostate cancer.
|
Cancer
|
2011
|
0.75
|
|
121
|
Prostate cancer biomarkers to improve risk stratification: is our knowledge of prostate cancer sufficient to spare prostate biopsies safely?
|
Eur Urol
|
2011
|
0.75
|
|
122
|
How common is PSA screening in elderly men with limited life expectancies?
|
Nat Clin Pract Urol
|
2007
|
0.75
|
|
123
|
Is prostate cancer screening bad or good? Summary of a debate at the innovation in urology meeting, September 17-19, 2010, Milan, Italy.
|
Eur Urol
|
2010
|
0.75
|
|
124
|
Words of wisdom. Re: prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
|
Eur Urol
|
2007
|
0.75
|
|
125
|
Propensity score matching, competing risk analysis, and a competing risk nomogram: some guidance for urologists may be in place.
|
Eur Urol
|
2011
|
0.75
|
|
126
|
[Early detection of prostate cancer--recommendations after 13 years of follow-up in the European randomised study].
|
Ned Tijdschr Geneeskd
|
2015
|
0.75
|
|
127
|
Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017.
|
Curr Opin Urol
|
2017
|
0.75
|
|
128
|
Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.
|
BJU Int
|
2012
|
0.75
|
|
129
|
Overestimation of prostate cancer mortality and other-cause mortality by the Kaplan-Meier method.
|
Can J Urol
|
2013
|
0.75
|
|
130
|
Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
|
Cancer
|
2005
|
0.75
|
|
131
|
Screening for prostate cancer: have we resolved the controversy?
|
Curr Opin Support Palliat Care
|
2010
|
0.75
|
|
132
|
Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort.
|
Eur J Cancer
|
2012
|
0.75
|
|
133
|
[Guidelines on the early detection of prostate cancer].
|
Ned Tijdschr Geneeskd
|
2015
|
0.75
|
|
134
|
Detection characteristics in randomized prostate screening.
|
Clin Cancer Res
|
2004
|
0.75
|